Investing.com - BioLineRx reported on Tuesday second quarter earnings that missed analysts' forecasts and revenue that was inline with expectations.
BioLineRx announced earnings per share of $-0.1493 on revenue of $0.00. Analysts polled by Investing.com anticipated EPS of $-0.13 on revenue of $0.00.
BioLineRx shares are down 12.25% from the beginning of the year, still down 43.17% from its 52 week high of $3.15 set on October 15, 2021. They are outperforming the Nasdaq which is down 16.25% from the start of the year.
BioLineRx follows other major Healthcare sector earnings this month
BioLineRx's report follows an earnings beat by J&J on July 19, who reported EPS of $2.59 on revenue of $24.02B, compared to forecasts EPS of $2.54 on revenue of $23.77B.
Eli Lilly had missed expectations on August 4 with second quarter EPS of $1.25 on revenue of $6.49B, compared to forecast for EPS of $1.7 on revenue of $6.85B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar